Summary

Location
at La Jolla, California and other locations
Dates
study started
completion around

Description

Summary

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

Keywords

Solid and Hematological Malignancies, Hematologic Neoplasms, Axicabtagene ciloleucel, Brexucabtagene autoleucel, KITE-585, KITE-718, KITE-439, KITE-222, KITE-363, Axicabtagene Ciloleucel (KTE-C19 ), Brexucabtagene Autoleucel (KTE-X19)

Eligibility

You can join if…

  • The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable
  • The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
  • In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

You CAN'T join if...

none

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • Children's Hospital of Orange County
    Orange California 92868 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Kite, A Gilead Company
Links
Gilead Clinical Trials Website
ID
NCT05041309
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 700 study participants
Last Updated